Identification of urgent gaps in public and policymaker knowledge of heart failure: Results of a global survey.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
30 05 2023
Historique:
received: 25 03 2022
accepted: 08 03 2023
medline: 1 6 2023
pubmed: 31 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Despite advances in the treatment of heart failure (HF) with reduced ejection fraction, people with HF continue to have a high risk of mortality and hospitalisation. Patients also suffer from poor quality of life, with reduced societal and economic participation. The burden of HF on patients and healthcare systems is extraordinary, yet awareness remains low. This survey was conducted to identify gaps in general public and policymaker knowledge around HF. A closed-question web-based survey of the general public and policymakers was conducted between February and October 2020. Study outcomes assessed the participants' awareness and understanding of HF symptoms, risk factors and mortality, and views around hospital admissions in their country. Responses were collected using multiple-choice questions. The survey was completed by 26,272 general public respondents in 13 countries and 281 government and public sector policymakers in nine countries. While 99% of general public respondents had heard of HF, their understanding of the condition and its symptoms was poor, and only 6% identified that shortness of breath, fatigue, and leg swelling were the main symptoms of HF. Of policymaker respondents, 14% identified HF as the leading cause of avoidable hospitalisations, and only 4% recognised that ~ 87% of government spending on HF is related to hospitalisations. Major gaps were identified in the understanding of HF and the burden it places on patients and their caregivers, healthcare systems and society. This study confirms an ongoing need for national policy strategies and investment to raise awareness of the importance of HF prevention, early diagnosis, and implementation of effective treatments to reduce hospitalisations and death.

Sections du résumé

BACKGROUND
Despite advances in the treatment of heart failure (HF) with reduced ejection fraction, people with HF continue to have a high risk of mortality and hospitalisation. Patients also suffer from poor quality of life, with reduced societal and economic participation. The burden of HF on patients and healthcare systems is extraordinary, yet awareness remains low. This survey was conducted to identify gaps in general public and policymaker knowledge around HF.
METHODS
A closed-question web-based survey of the general public and policymakers was conducted between February and October 2020. Study outcomes assessed the participants' awareness and understanding of HF symptoms, risk factors and mortality, and views around hospital admissions in their country. Responses were collected using multiple-choice questions.
RESULTS
The survey was completed by 26,272 general public respondents in 13 countries and 281 government and public sector policymakers in nine countries. While 99% of general public respondents had heard of HF, their understanding of the condition and its symptoms was poor, and only 6% identified that shortness of breath, fatigue, and leg swelling were the main symptoms of HF. Of policymaker respondents, 14% identified HF as the leading cause of avoidable hospitalisations, and only 4% recognised that ~ 87% of government spending on HF is related to hospitalisations.
CONCLUSIONS
Major gaps were identified in the understanding of HF and the burden it places on patients and their caregivers, healthcare systems and society. This study confirms an ongoing need for national policy strategies and investment to raise awareness of the importance of HF prevention, early diagnosis, and implementation of effective treatments to reduce hospitalisations and death.

Identifiants

pubmed: 37254075
doi: 10.1186/s12889-023-15405-4
pii: 10.1186/s12889-023-15405-4
pmc: PMC10227786
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1023

Subventions

Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Arch Med Sci. 2014 May 12;10(2):355-60
pubmed: 24904672
J Am Coll Cardiol. 2019 May 14;73(18):2354-2355
pubmed: 31072580
Eur J Heart Fail. 2015 Feb;17(2):169-76
pubmed: 25756844
Eur Heart J. 2005 Nov;26(22):2413-21
pubmed: 16135524
Int J Cardiol. 2014 Feb 15;171(3):368-76
pubmed: 24398230
ESC Heart Fail. 2014 Dec;1(2):110-145
pubmed: 28834628
ESC Heart Fail. 2017 Aug;4(3):224-231
pubmed: 28772053
Glob Heart. 2019 Sep;14(3):197-214
pubmed: 31451235
Pharmacoeconomics. 2008;26(6):447-62
pubmed: 18489197
BMC Cardiovasc Disord. 2018 May 2;18(1):74
pubmed: 29716540
Cien Saude Colet. 2020 Mar;25(4):1375-1388
pubmed: 32267439
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Eur J Cardiothorac Surg. 2019 Jun 1;55(Suppl 1):i3-i10
pubmed: 31106335
J Clin Med. 2022 Feb 07;11(3):
pubmed: 35160314
Mayo Clin Proc. 2010 Feb;85(2):180-95
pubmed: 20118395
Lancet. 2019 Mar 9;393(10175):1034-1044
pubmed: 30860029
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
Eur J Heart Fail. 2017 Sep;19(9):1095-1104
pubmed: 28470962
Nat Rev Cardiol. 2016 Jun;13(6):368-78
pubmed: 26935038
Heart. 2018 Apr;104(7):600-605
pubmed: 28982720
Arch Cardiovasc Dis. 2014 Mar;107(3):158-68
pubmed: 24662470
Health Psychol Open. 2019 Apr 23;6(1):2055102919844504
pubmed: 31041109
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Cardiovasc Diagn Ther. 2020 Apr;10(2):244-251
pubmed: 32420107
Heart. 2019 May;105(9):663-664
pubmed: 30647095
Cardiovasc J Afr. 2022 Jul-Aug 23;33(4):180-185
pubmed: 35080578
J Geriatr Cardiol. 2016 Feb;13(2):115-7
pubmed: 27168735
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
ESC Heart Fail. 2019 Aug;6(4):603-612
pubmed: 31054212
Eur J Heart Fail. 2018 Nov;20(11):1505-1535
pubmed: 29806100
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
ESC Heart Fail. 2014 Sep;1(1):4-25
pubmed: 28834669
Circulation. 2017 Mar 28;135(13):1214-1223
pubmed: 28174193

Auteurs

Carolyn S P Lam (CSP)

National Heart Centre Singapore, Duke-NUS Medical School, 169857, Singapore, Singapore. carolyn.lam@duke-nus.edu.sg.

Ed Harding (E)

The Health Policy Partnership, WC2N 4JS, London, UK.

Marc Bains (M)

The HeartLife Foundation, V5X 1E7, Vancouver, BC, Canada.

Alex Chin (A)

AstraZeneca, Global Medical Affairs, 20878, Gaithersburg, MD, USA.

Naresh Kanumilli (N)

Northenden Group Practice, M22 4DH, Northenden, Manchester, UK.

Mark C Petrie (MC)

Institute of Cardiovascular and Medical Sciences, The University Court of the University of Glasgow, G12 8QQ, Glasgow, UK.

Paula Pohja-Hutchison (P)

AstraZeneca, Global Corporate Affairs, CB2 8PA, Cambridge, UK.

Jiefu Yang (J)

Department of Cardiology, Beijing Hospital, National Center of Gerontology China, 100730, Beijing, China.

Javed Butler (J)

Department of Medicine, University of Mississippi Medical Center, 39216, Jackson, MS, USA. butlzih@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH